LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: The influence of vitamin-C intake on blood glucose measurements in COVID-19 pandemic.

    Al-Obaidi, Zaid Mahdi Jaber / Hussain, Yasmeen Ali / Ali, Alaa A / Al-Rekabi, Mohammed Dakhil

    Journal of infection in developing countries

    2021  Volume 15, Issue 2, Page(s) 209–213

    Abstract: Introduction: Coronavirus disease 2019 (COVID-19) is declared as pandemic by the World Health Orgnazation (WHO) on March 2020. One of the heavily utilized measures during this pandemic is vitamin C (aka ascorbic acid). Unfortunately, vitamin C has been ... ...

    Abstract Introduction: Coronavirus disease 2019 (COVID-19) is declared as pandemic by the World Health Orgnazation (WHO) on March 2020. One of the heavily utilized measures during this pandemic is vitamin C (aka ascorbic acid). Unfortunately, vitamin C has been associated with glucose measurement interference and thus this study highlights the elevated levels of blood glucose correlated with the presence of vitamin C interference.
    Methodology: Thirty samples were selected randomly and the blood glucose were measured prior and post the addition of spiked standard concentrations of vitamin C. The interference of vitamin C with glucose readings in COVID-19 pandemic were evaluated and observed employing the Auto Chemistry Analyzer machine.
    Results: The addition of ascorbic acid (vitamin C) standards (spikes) into the isolated samples shows a correlated increment in the reading measures. Thereafter, the increments of Random Blood Sugar (RBS) readings after being spiked with the vitamin C standards shows a logarithmic correlation with good interesting R-squared (R2 = 0.9921).
    Conclusions: The authors find that the presence of vitamin C in blood actively and significantly alters the glucose level readings especially with the highly consumption of vitamin C during the COVID-19 pandemic.
    MeSH term(s) Ascorbic Acid/administration & dosage ; Ascorbic Acid/blood ; Blood Glucose/analysis ; COVID-19 ; Humans
    Chemical Substances Blood Glucose ; Ascorbic Acid (PQ6CK8PD0R)
    Language English
    Publishing date 2021-03-07
    Publishing country Italy
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2394024-4
    ISSN 1972-2680 ; 2036-6590
    ISSN (online) 1972-2680
    ISSN 2036-6590
    DOI 10.3855/jidc.13960
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Does CCL19 act as a double-edged sword in cancer development?

    Gowhari Shabgah, Arezoo / Al-Obaidi, Zaid Mahdi Jaber / Sulaiman Rahman, Heshu / Kamal Abdelbasset, Walid / Suksatan, Wanich / Bokov, Dmitry O / Thangavelu, Lakshmi / Turki Jalil, Abduladheem / Jadidi-Niaragh, Farhad / Mohammadi, Hamed / Mashayekhi, Kazem / Gholizadeh Navashenaq, Jamshid

    Clinical and experimental immunology

    2022  Volume 207, Issue 2, Page(s) 164–175

    Abstract: Cancer is considered a life-threatening disease, and several factors are involved in its development. Chemokines are small proteins that physiologically exert pivotal roles in lymphoid and non-lymphoid tissues. The imbalance or dysregulation of ... ...

    Abstract Cancer is considered a life-threatening disease, and several factors are involved in its development. Chemokines are small proteins that physiologically exert pivotal roles in lymphoid and non-lymphoid tissues. The imbalance or dysregulation of chemokines has contributed to the development of several diseases, especially cancer. CCL19 is one of the homeostatic chemokines that is abundantly expressed in the thymus and lymph nodes. This chemokine, which primarily regulates immune cell trafficking, is involved in cancer development. Through the induction of anti-tumor immune responses and inhibition of angiogenesis, CCL19 exerts tumor-suppressive functions. In contrast, CCL19 also acts as a tumor-supportive factor by inducing inflammation, cell growth, and metastasis. Moreover, CCL19 dysregulation in several cancers, including colorectal, breast, pancreatic, and lung cancers, has been considered a tumor biomarker for diagnosis and prognosis. Using CCL19-based therapeutic approaches has also been proposed to overcome cancer development. This review will shed more light on the multifarious function of CCL19 in cancer and elucidate its application in diagnosis, prognosis, and even therapy. It is expected that the study of CCL19 in cancer might be promising to broaden our knowledge of cancer development and might introduce novel approaches in cancer management.
    MeSH term(s) Chemokine CCL19/metabolism ; Chemokines/metabolism ; Humans ; Lung Neoplasms/metabolism ; Lymph Nodes ; Neovascularization, Pathologic ; Prognosis ; Receptors, CCR7/metabolism
    Chemical Substances CCL19 protein, human ; Chemokine CCL19 ; Chemokines ; Receptors, CCR7
    Language English
    Publishing date 2022-01-11
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 218531-3
    ISSN 1365-2249 ; 0009-9104 ; 0964-2536
    ISSN (online) 1365-2249
    ISSN 0009-9104 ; 0964-2536
    DOI 10.1093/cei/uxab039
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 337: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients.

    Marofi, Faroogh / Rahman, Heshu Sulaiman / Al-Obaidi, Zaid Mahdi Jaber / Jalil, Abduladheem Turki / Abdelbasset, Walid Kamal / Suksatan, Wanich / Dorofeev, Aleksei Evgenievich / Shomali, Navid / Chartrand, Max Stanley / Pathak, Yashwant / Hassanzadeh, Ali / Baradaran, Behzad / Ahmadi, Majid / Saeedi, Hossein / Tahmasebi, Safa / Jarahian, Mostafa

    Stem cell research & therapy

    2021  Volume 12, Issue 1, Page(s) 465

    Abstract: Acute myeloid leukemia (AML) is a serious, life-threatening, and hardly curable hematological malignancy that affects the myeloid cell progenies and challenges patients of all ages but mostly occurs in adults. Although several therapies are available ... ...

    Abstract Acute myeloid leukemia (AML) is a serious, life-threatening, and hardly curable hematological malignancy that affects the myeloid cell progenies and challenges patients of all ages but mostly occurs in adults. Although several therapies are available including chemotherapy, allogeneic hematopoietic stem cell transplantation (alloHSCT), and receptor-antagonist drugs, the 5-year survival of patients is quietly disappointing, less than 30%. alloHSCT is the major curative approach for AML with promising results but the treatment has severe adverse effects such as graft-versus-host disease (GVHD). Therefore, as an alternative, more efficient and less harmful immunotherapy-based approaches such as the adoptive transferring T cell therapy are in development for the treatment of AML. As such, chimeric antigen receptor (CAR) T cells are engineered T cells which have been developed in recent years as a breakthrough in cancer therapy. Interestingly, CAR T cells are effective against both solid tumors and hematological cancers such as AML. Gradually, CAR T cell therapy found its way into cancer therapy and was widely used for the treatment of hematologic malignancies with successful results particularly with somewhat better results in hematological cancer in comparison to solid tumors. The AML is generally fatal, therapy-resistant, and sometimes refractory disease with a disappointing low survival rate and weak prognosis. The 5-year survival rate for AML is only about 30%. However, the survival rate seems to be age-dependent. Novel CAR T cell therapy is a light at the end of the tunnel. The CD19 is an important target antigen in AML and lymphoma and the CAR T cells are engineered to target the CD19. In addition, a lot of research goes on the discovery of novel target antigens with therapeutic efficacy and utilizable for generating CAR T cells against various types of cancers. In recent years, many pieces of research on screening and identification of novel AML antigen targets with the goal of generation of effective anti-cancer CAR T cells have led to new therapies with strong cytotoxicity against cancerous cells and impressive clinical outcomes. Also, more recently, an improved version of CAR T cells which were called modified or smartly reprogrammed CAR T cells has been designed with less unwelcome effects, less toxicity against normal cells, more safety, more specificity, longer persistence, and proliferation capability. The purpose of this review is to discuss and explain the most recent advances in CAR T cell-based therapies targeting AML antigens and review the results of preclinical and clinical trials. Moreover, we will criticize the clinical challenges, side effects, and the different strategies for CAR T cell therapy.
    MeSH term(s) Humans ; Immunotherapy ; Immunotherapy, Adoptive ; Leukemia, Myeloid, Acute/therapy ; Receptors, Chimeric Antigen/genetics ; T-Lymphocytes
    Chemical Substances Receptors, Chimeric Antigen
    Language English
    Publishing date 2021-08-20
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2548671-8
    ISSN 1757-6512 ; 1757-6512
    ISSN (online) 1757-6512
    ISSN 1757-6512
    DOI 10.1186/s13287-021-02420-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients

    Faroogh Marofi / Heshu Sulaiman Rahman / Zaid Mahdi Jaber Al-Obaidi / Abduladheem Turki Jalil / Walid Kamal Abdelbasset / Wanich Suksatan / Aleksei Evgenievich Dorofeev / Navid Shomali / Max Stanley Chartrand / Yashwant Pathak / Ali Hassanzadeh / Behzad Baradaran / Majid Ahmadi / Hossein Saeedi / Safa Tahmasebi / Mostafa Jarahian

    Stem Cell Research & Therapy, Vol 12, Iss 1, Pp 1-

    2021  Volume 23

    Abstract: Abstract Acute myeloid leukemia (AML) is a serious, life-threatening, and hardly curable hematological malignancy that affects the myeloid cell progenies and challenges patients of all ages but mostly occurs in adults. Although several therapies are ... ...

    Abstract Abstract Acute myeloid leukemia (AML) is a serious, life-threatening, and hardly curable hematological malignancy that affects the myeloid cell progenies and challenges patients of all ages but mostly occurs in adults. Although several therapies are available including chemotherapy, allogeneic hematopoietic stem cell transplantation (alloHSCT), and receptor-antagonist drugs, the 5-year survival of patients is quietly disappointing, less than 30%. alloHSCT is the major curative approach for AML with promising results but the treatment has severe adverse effects such as graft-versus-host disease (GVHD). Therefore, as an alternative, more efficient and less harmful immunotherapy-based approaches such as the adoptive transferring T cell therapy are in development for the treatment of AML. As such, chimeric antigen receptor (CAR) T cells are engineered T cells which have been developed in recent years as a breakthrough in cancer therapy. Interestingly, CAR T cells are effective against both solid tumors and hematological cancers such as AML. Gradually, CAR T cell therapy found its way into cancer therapy and was widely used for the treatment of hematologic malignancies with successful results particularly with somewhat better results in hematological cancer in comparison to solid tumors. The AML is generally fatal, therapy-resistant, and sometimes refractory disease with a disappointing low survival rate and weak prognosis. The 5-year survival rate for AML is only about 30%. However, the survival rate seems to be age-dependent. Novel CAR T cell therapy is a light at the end of the tunnel. The CD19 is an important target antigen in AML and lymphoma and the CAR T cells are engineered to target the CD19. In addition, a lot of research goes on the discovery of novel target antigens with therapeutic efficacy and utilizable for generating CAR T cells against various types of cancers. In recent years, many pieces of research on screening and identification of novel AML antigen targets with the goal of generation of ...
    Keywords Acute myeloid leukemia ; Adoptive cell therapy ; Chimeric antigen receptor T cells ; Hematological malignancy ; Target antigen ; Medicine (General) ; R5-920 ; Biochemistry ; QD415-436
    Subject code 610
    Language English
    Publishing date 2021-08-01T00:00:00Z
    Publisher BMC
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top